Search research articles
Contact Us
Filters
Showing results (261-270 of 302) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
William C Zamboni, Laura L Jung, Merrill J Egorin, et al.
BMC Medical Genomics
|
June 20, 2014
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer
Vijayalakshmi Shanmugam, Ramesh K Ramanathan, Nicole A Lavender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
Journal of Gastrointestinal Oncology
|
January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
Daniel D Von Hoff, Ramesh K Ramanathan, Mitesh J Borad, et al.
JAMA Oncology
|
October 4, 2019
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial
Gayle S Jameson, Erkut Borazanci, Hani M Babiker, et al.
American Journal of Clinical Oncology
|
October 11, 2008
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
Y Yen, Dean W Lim, Vincent Chung, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
D Mahadevan, E G Chiorean, W B Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Daniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.
Page
of 31
Search research articles
Search
Showing results (261-270 of 302) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
William C Zamboni, Laura L Jung, Merrill J Egorin, et al.
BMC Medical Genomics
|
June 20, 2014
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer
Vijayalakshmi Shanmugam, Ramesh K Ramanathan, Nicole A Lavender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
Journal of Gastrointestinal Oncology
|
January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
Daniel D Von Hoff, Ramesh K Ramanathan, Mitesh J Borad, et al.
JAMA Oncology
|
October 4, 2019
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial
Gayle S Jameson, Erkut Borazanci, Hani M Babiker, et al.
American Journal of Clinical Oncology
|
October 11, 2008
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
Y Yen, Dean W Lim, Vincent Chung, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
D Mahadevan, E G Chiorean, W B Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Daniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.
Page
of 31